Stephen Lade

6.3k total citations · 3 hit papers
46 papers, 3.2k citations indexed

About

Stephen Lade is a scholar working on Pathology and Forensic Medicine, Dermatology and Oncology. According to data from OpenAlex, Stephen Lade has authored 46 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 18 papers in Dermatology and 14 papers in Oncology. Recurrent topics in Stephen Lade's work include Lymphoma Diagnosis and Treatment (21 papers), Cutaneous lymphoproliferative disorders research (18 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Stephen Lade is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Cutaneous lymphoproliferative disorders research (18 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Stephen Lade collaborates with scholars based in Australia, United States and Canada. Stephen Lade's co-authors include H. Miles Prince, Stephen B. Fox, Joshy George, Nadia Traficante, Richard W. Tothill, Robert Brown, Dariush Etemadmoghadam, Izhak Haviv, Yoke-Eng Chiew and Dorota M. Gertig and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stephen Lade

43 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

2008 1.0k citations Richard W. Tothill, Anna V. Tinker et al. Clinical Cancer Research profile →
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations H. Miles Prince, David Joske et al. profile →
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Lade Australia	20	1.1k	1.1k	909	689	669	46	3.2k
Bjarni A. Agnarsson Iceland	27	925 0.8×	854 0.8×	714 0.8×	556 0.8×	331 0.5×	80	2.7k
Ashley Cimino‐Mathews United States	37	924 0.8×	655 0.6×	2.2k 2.4×	922 1.3×	405 0.6×	122	3.8k
Brian Skinnider Canada	33	752 0.7×	2.3k 2.2×	1.7k 1.9×	327 0.5×	319 0.5×	70	3.8k
Farid Moinfar Austria	31	925 0.8×	951 0.9×	955 1.1×	1.1k 1.6×	740 1.1×	80	3.1k
Asma Tulbah Saudi Arabia	31	880 0.8×	496 0.5×	1.9k 2.1×	837 1.2×	136 0.2×	104	3.3k
Thierry Lesimple France	32	1.2k 1.0×	476 0.4×	2.0k 2.2×	401 0.6×	214 0.3×	139	3.3k
Carmen Tornos United States	38	950 0.9×	750 0.7×	916 1.0×	571 0.8×	279 0.4×	91	4.4k
Lee K. Tan United States	36	957 0.9×	2.2k 2.1×	1.8k 2.0×	2.6k 3.8×	313 0.5×	59	5.1k
Yan‐Gao Man United States	28	1.3k 1.2×	480 0.5×	1.2k 1.3×	1.1k 1.5×	281 0.4×	95	3.1k
Kuan‐Ting Kuo Taiwan	27	1.1k 1.0×	567 0.5×	643 0.7×	552 0.8×	51 0.1×	85	2.7k

Countries citing papers authored by Stephen Lade

Since Specialization

Citations

This map shows the geographic impact of Stephen Lade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Lade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Lade more than expected).

Fields of papers citing papers by Stephen Lade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Lade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Lade. The network helps show where Stephen Lade may publish in the future.

Co-authorship network of co-authors of Stephen Lade

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Lade. A scholar is included among the top collaborators of Stephen Lade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Lade. Stephen Lade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Handunnetti, Sasanka M., Amit Khot, Piers Blombery, et al.. (2025). Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Advances. 10(5). 1733–1742.

Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations

Hapgood, Greg, Maya Latimer, Sze Ting Lee, et al.. (2021). Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 52(10). 1806–1817.

MacManus, Michael, Daniel Roos, Peter C. O’Brien, et al.. (2021). Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. European Journal of Cancer. 152. 129–138. 7 indexed citations

McEvoy, Christopher R., Holly Holliday, Niko Thio, et al.. (2020). A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Laboratory Investigation. 101(1). 26–37. 16 indexed citations

Busuttil, Rita A., Joshy George, Colin M. House, et al.. (2020). SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer. 24(3). 589–601. 13 indexed citations

McCormack, Christopher, Jillian Wells, Belinda A. Campbell, et al.. (2020). Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australasian Journal of Dermatology. 62(1). e8–e18. 8 indexed citations

Nalankilli, Kumanan, et al.. (2019). Increasing rates of SSA/P detection in a large open-access Australian colonoscopy cohort. SHILAP Revista de lepidopterología. 7(3). E310–E316. 4 indexed citations

Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2019). Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood. 134(Supplement_1). 756–756. 25 indexed citations

10.

Handunnetti, Sasanka M., Amit Khot, Mary Ann Anderson, et al.. (2019). Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. Blood. 134(Supplement_1). 3999–3999. 6 indexed citations

11.

Blombery, Piers, Ella R. Thompson, Georgina L. Ryland, et al.. (2018). Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget. 9(90). 36126–36136. 57 indexed citations

12.

Hu, Honghua, Khalid Johani, Ahmad Almatroudi, et al.. (2016). Bacterial Biofilm Infection Detected in Breast Implant–Associated Anaplastic Large-Cell Lymphoma. Plastic & Reconstructive Surgery. 137(6). 1659–1669. 241 indexed citations

13.

Knight, R., Mark Magnusson, Tony Connell, et al.. (2016). Abstract: Epidemiology and Risk Factors for Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in Australia & New Zealand. Plastic & Reconstructive Surgery Global Open. 4(9S). 94–95. 3 indexed citations

14.

Khot, Amit, Christopher McCormack, Stephen Lade, et al.. (2014). Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 125(1). 71–81. 153 indexed citations

15.

Tothill, Richard W., Anna V. Tinker, Joshy George, et al.. (2008). Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research. 14(16). 5198–5208. 1041 indexed citations breakdown →

16.

Prince, H. Miles, et al.. (2008). Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. Journal of the American Academy of Dermatology. 59(4). 589–595. 30 indexed citations

17.

Prince, H. Miles, et al.. (2008). Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 112(8). 3082–3087. 137 indexed citations

18.

Seshadri, Tara, Debra A. Gook, Stephen Lade, et al.. (2006). Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. British Journal of Cancer. 94(7). 1007–1010. 58 indexed citations

19.

Ng, Ashley P., et al.. (2006). Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases.. PubMed. 91(1). 143–4. 34 indexed citations

20.

Farmer, K. Chip, Campbell Penfold, Jeremy Millar, et al.. (2002). Rectal cancer in Victoria in 1994: Patterns of reported management. ANZ Journal of Surgery. 72(4). 265–270. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact